Aromatase inhibitors in postmenopausal breast cancer patients

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 3, 2005, Pages 309-314

  Rieber, Alyssa G ^a,b   Theriault, Richard L ^a,b  

^a University of Texas M D Anderson Cancer Center ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Postmenopausal

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; DOXORUBICIN; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTHRALGIA; ARTHRITIS; BREAST CANCER; CLINICAL TRIAL; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HORMONAL THERAPY; HUMAN; METASTASIS; MYALGIA; POSTMENOPAUSE; PRACTICE GUIDELINE; REVIEW; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CANCER STAGING; FEMALE; PATHOLOGY; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 24944431563     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0018     Document Type: Review

References (25)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104-107.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-1467.
4. Smith IE. Drug therapy: aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-2442.
5. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-1411.
6. Bonneterre J, Buzdar A, Nabholtz JMA, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-2258.
7. Nabholtz JMA, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-3767.
8. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;10:2596-2606.
9. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-2109.
10. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391-1398.
11. Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): a randomized phase III trial of the EORTC Breast Group (Abstr #515). Proc Am Soc Clin Oncol 2004;23.
12. Carlson RW, Edge SB, McCormick B, Theriault R, et al. Clinical Practice Guidelines in Oncology version 1.2005. National Comprehensive Cancer Network. Available at http://www.nccn.org. Accessed April 18, 2005.
13. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-2139.
14. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
15. The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
16. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-629.
17. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684-690.
18. Gosss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
19. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
20. Eiermann W, Paepke S, Appelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
21. Semiglazov VF, Semiglazov VV, Ivanov VG, et al. Neoadjuvant endocrine therapy: exemestane (E) vs. tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4 N1-2 MO) (Abstr #111). Breast Cancer Res Treat 2003;83(suppl 1):S22.
22. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 2002;20:3628-3636.
23. Semiglazov VF, Ivanov VG, Semiglazov VV, et al. Neoadjuvant endocrine therapy vs. chemotherapy for postmenopausal ER-positive breast cancer patients. Poster presentation at San Antonio Breast Conference, San Antonio, TX; December 9, 2004.
24. Rose C, Vtoraya O, Pluzanska A, et al. An open randomized trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318-2327.
25. Dunn BK, Wickerham DL, Ford LG. Prevention of hormone-related cancers: breast cancer. J Clin Oncol 2005;23:357-367.